SCHEMBL10132121

SCHEMBL10132121

O=C(Nc1cccc(OCc2ccccc2)c1)c1ccc(O)cc1O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.60
MAOB P27338 1/20 0.59
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
SGMS2 Q8NHU3 1/20 0.55
GAA P10253 1/20 0.55
CTSV O60911 1/20 0.55
CTSL P07711 1/20 0.55
LRRK2 Q5S007 1/20 0.54
PDK1 Q15118 1/20 0.54
PDK2 Q15119 1/20 0.54
PDK3 Q15120 1/20 0.54
PDK4 Q16654 1/20 0.54
MET P08581 1/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
SIRT2 Q8IXJ6 1/20 0.53
RXFP1 Q9HBX9 1/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132123 0.89 MEN1 (0.69) NR1H4MAOBMEN1KMT2ALRRK2
SCHEMBL13189711 0.82 P2RX1 (0.65) NR1H4MEN1KMT2ALRRK2
SCHEMBL11550139 0.82 NR1H4 (0.81) NR1H4MAOBMEN1KMT2ANPC1
SCHEMBL5226707 0.81 NR1H4 (0.61) NR1H4MEN1KMT2ASGMS2GAA
SCHEMBL11779160 0.81 KMT2A (0.63) NR1H4MEN1KMT2ASGMS2CTSV
SCHEMBL2272936 0.81 RAB9A (0.61) KMT2AGAANPC1RAB9ARXFP1
SCHEMBL22647160 0.81 MEN1 (0.55) NR1H4MAOBMEN1KMT2ASGMS2
SCHEMBL5249717 0.80 NR1H4 (0.65) NR1H4MAOBMEN1KMT2ACTSV
SCHEMBL13812749 0.80 MET (0.60) NR1H4MEN1KMT2AGAALRRK2
SCHEMBL1096228 0.80 KMT2A (0.68) MAOBMEN1KMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 NR1H4 3084/4885MAOB 3460/4885MEN1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.